High Deal Valuations & Volumes Will Persist, Industry Dealmakers Predict

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.

Close up top view of young business people putting their hands together.
Industry leaders expect lots of partnering in 2021 • Source: Shutterstock

Industry business development leaders expect an active deal-making year in 2021 but that high valuations for biotech assets will continue to be a challenge for big pharmaceutical companies looking to fill their pipelines. Executives from AbbVie Inc., Amgen, Inc., AstraZeneca PLC, Genentech, Inc. and Boehringer Ingelheim GmbH discussed the business development landscape for pharma during a panel session at the Biocom Global Life Science Partnering Conference on 24 February.

The COVID-19 pandemic has thrown the industry a curveball on multiple fronts, but despite business disruptions caused by the global...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.